Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

171260 AMPK Inhibitor, Compound C - CAS 866405-64-3 - Calbiochem

AMPK Inhibitor, Compound C, CAS 866405-64-3, is a cell-permeable compound that inhibits KDR/VEGFR2, ALK2/BMPR-I, and AMPK kinase activities (IC₅₀ = 25.1, 148, and 234.6 nM, respectively).

MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.

Synonyms: 6-[4-(2-Piperidin-1-yl-ethoxy)-phenyl)]-3-pyridin-4-yl-pyrrazolo[1,5-a]-pyrimidine, Dorsomorphin, AMPK Inhibitor I, BMP Inhibitor I

Primary Target: AMPK
View Products on Sigmaaldrich.com
171260
Purchase on Sigma-Aldrich

Overview

Replacement Information

Key Spec Table

CAS #Empirical Formula
866405-64-3C₂₄H₂₅N₅O

Products

Catalogue NumberPackaging Qty/Pack
171260-10MGCN Plastic ampoule 10 mg
171260-1MGCN Plastic ampoule 1 mg
171260-5MGCN Plastic ampoule 5 mg
Description
OverviewA cell-permeable pyrrazolopyrimidine compound that inhibits against KDR/VEGFR2, ALK2/BMPR-I, AMPK kinase activity (IC50 = 25.1, 148, and 234.6 nM, respectively), while exhibiting much reduced or little effect toward ALK5/TGFβR-I, ZAPK, Syk, PKCθ, PKA, or JAK3. Shown to block both BMP pathway-dependent dorsoventral development (EC100 = 2.5 µM) and VEGF signaling-dependent intersomitic vessel formation (EC50 = 5 µM) in zebrafish embryo in vivo. Commonly used in combination with AMPK activators AICAR (Cat. No. 123040) and/or Metformin (Cat. No. 317240) for studying AMPK-dependent cellular events in vitro and physiological responses in animals in vivo. Also available as a 10 mM solution in DMSO (Cat. No. 171261).
Catalogue Number171260
Brand Family Calbiochem®
Synonyms6-[4-(2-Piperidin-1-yl-ethoxy)-phenyl)]-3-pyridin-4-yl-pyrrazolo[1,5-a]-pyrimidine, Dorsomorphin, AMPK Inhibitor I, BMP Inhibitor I
References
ReferencesHao, J., et al. 2010. ACS Chem.Biol. 5, 245.
Yu, P.B., et al. 2008. Nat. Chem. Biol 4, 33.
Kim, E.K., et al. 2004. J. Biol. Chem. 279, 19970.
Lee, M., et al. 2003. J. Biol. Chem. 278, 39653.
Inoki, K., et al. 2003. Cell 115, 577.
Fryer, L.G., 2002. FEBS Lett. 531, 189.
Zhou, G., et al. 2001. J. Clin. Invest. 108, 1167.
Product Information
CAS number866405-64-3
ATP CompetitiveY
FormLight yellow solid
Hill FormulaC₂₄H₂₅N₅O
Chemical formulaC₂₄H₂₅N₅O
ReversibleY
Structure formula ImageStructure formula Image
Quality LevelMQ100
Applications
Biological Information
Primary TargetAMPK
Primary Target IC<sub>50</sub>25.1, 148, and 234.6 nM, against KDR/VEGFR2, ALK2/BMPR-I, AMPK kinase activity, respectively
Primary Target K<sub>i</sub>EC100 = 2.5 µM against BMP pathway-dependent dorsoventral development; EC50 = 5 µM against VEGF signaling-dependent intersomitic vessel formation in zebrafish embryo in vivo
Purity≥95% by HPLC
Physicochemical Information
Cell permeableY
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
Toxicity Standard Handling
Storage +2°C to +8°C
Protect from Light Protect from light
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Packaging Information
Packaged under inert gas Packaged under inert gas
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Catalogue Number GTIN
171260-10MGCN 04055977207156
171260-1MGCN 04055977207149
171260-5MGCN 04055977207163

Documentation

AMPK Inhibitor, Compound C - CAS 866405-64-3 - Calbiochem SDS

Title

Safety Data Sheet (SDS) 

AMPK Inhibitor, Compound C - CAS 866405-64-3 - Calbiochem Certificates of Analysis

TitleLot Number
171260

References

Reference overview
Hao, J., et al. 2010. ACS Chem.Biol. 5, 245.
Yu, P.B., et al. 2008. Nat. Chem. Biol 4, 33.
Kim, E.K., et al. 2004. J. Biol. Chem. 279, 19970.
Lee, M., et al. 2003. J. Biol. Chem. 278, 39653.
Inoki, K., et al. 2003. Cell 115, 577.
Fryer, L.G., 2002. FEBS Lett. 531, 189.
Zhou, G., et al. 2001. J. Clin. Invest. 108, 1167.
Data Sheet

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision22-March-2012 JSW
Synonyms6-[4-(2-Piperidin-1-yl-ethoxy)-phenyl)]-3-pyridin-4-yl-pyrrazolo[1,5-a]-pyrimidine, Dorsomorphin, AMPK Inhibitor I, BMP Inhibitor I
DescriptionA cell-permeable pyrrazolopyrimidine compound that inhibits against KDR/VEGFR2, ALK2/BMPR-I, AMPK kinase activity (IC50 = 25.1, 148, and 234.6 nM, respectively), while exhibiting much reduced or little effect toward ALK5/TGFβR-I, ZAPK, Syk, PKCθ, PKA, or JAK3. Shown to block both BMP pathway-dependent dorsoventral development (EC100 = 2.5 µM) and VEGF signaling-dependent intersomitic vessel formation (EC50 = 5 µM) in zebrafish embryo in vivo. Commonly used in combination with AMPK activators AICAR (Cat. No. 123040) and/or Metformin (Cat. No. 317240) for studying AMPK-dependent cellular events in vitro and physiological responses in animals in vivo. Also available as a 10 mM solution in DMSO (Cat. No. 171261).
FormLight yellow solid
Intert gas (Yes/No) Packaged under inert gas
CAS number866405-64-3
Chemical formulaC₂₄H₂₅N₅O
Structure formulaStructure formula
Purity≥95% by HPLC
SolubilityDMSO (4 mg/ml), 2% HCl (10 mg/ml), 2% Acetic Acid (10 mg/ml), or Methanol (3 mg/ml)
Storage Protect from light
+2°C to +8°C
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Toxicity Standard Handling
ReferencesHao, J., et al. 2010. ACS Chem.Biol. 5, 245.
Yu, P.B., et al. 2008. Nat. Chem. Biol 4, 33.
Kim, E.K., et al. 2004. J. Biol. Chem. 279, 19970.
Lee, M., et al. 2003. J. Biol. Chem. 278, 39653.
Inoki, K., et al. 2003. Cell 115, 577.
Fryer, L.G., 2002. FEBS Lett. 531, 189.
Zhou, G., et al. 2001. J. Clin. Invest. 108, 1167.